![CAR-T cells, CAR-Target, CD19, CD20, HER2](https://delivery-files.atcc.org/api/public/content/93857-CL-1562_1400x300.jpg)
One of the bottlenecks in CAR-T therapeutic development is evaluating the biofunction of effector cells. This in vitro process involves a series of labor-intensive co-culture immunoassays. To address this challenge, we generated luciferase reporter cell lines that have high endogenous expression of clinically relevant cell surface tumor antigens such as CD19, CD20, and HER2. These new immuno-oncology tools include both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression. These cells enable your immuno-therapeutic breakthroughs by allowing you to monitor the potency and efficacy of candidate CAR-T effector cells in your cytotoxicity and cell viability assays in real time.
Table 1: CAR-T Target Luciferase Reporter Cells
Designation | ATCC® No. | Disease | Target |
---|---|---|---|
WIL2-S-Luc2 |
CRL-8885-LUC2™ | B Cell Lymphoma | CD19 |
Raji-Luc2 | CCL-86-LUC2™ | Burkitt’s Lymphoma | CD19 |
Daudi-Luc2 | CCL-213-LUC2™ | Burkitt’s Lymphoma | CD20 |
Farage-Luc2 | CRL-2630-LUC2™ | Non-Hodgkin’s B Cell Lymphoma | CD20 |
BT-474-Luc2 | HTB-20-LUC2™ | Breast Ductal Carcinoma | HER2 |
These convenient reporter-labeled cells allow you to eliminate workflows involving radioactive or fluorescent dye labeling. The cells retain high expression of both the target antigen and luciferase up to 30 population doublings. These flexible target cells can also be incorporated in other immuno-oncology applications such as ADCC and natural killer (NK) cell cytotoxicity assays.
- High expression stability of both target antigen and luciferase
- High signal-to-noise ratio (S/N)
- Physiologically relevant low E:T ratios
- High-performing, fully authenticated cell lines
- Easy-to-use reporter system
- Real-time, live-cell imaging possible
CAR-T Effector Cell Efficacy Using Raji-Luc2 and WIL2-S-Luc2
CAR-T Target Luciferase Reporter-labeled Cells
Webinar
In this webinar, we present new luciferase reporter tumor cell lines that naturally express clinically relevant CAR-T target antigens on cell surface such as CD19, CD20 and HER2. Watch the webinar to see how these versatile reporter lines can be utilized to examine the function of CAR-T cells.
Application Note
To provide target cells for immuno-oncology researchers, we generated CAR-T Target Luciferase Reporter Cells. Read the application note to learn how these highly authenticated cells can help provide increased reproducibility in your CAR-T effector potency experiments.